Anti-Tuberculosis Drugs and Adverse Events

Hannah Yejin Kim; Jin-Gun Cho; Onno W Akkerman; Xavier Padanilam; Barbara Seaworth; Jan-Willem C Alffenaar

doi:10.1007/978-3-030-66703-0_13

Anti-Tuberculosis Drugs and Adverse Events

Hannah Yejin Kim, Jin-Gun Cho, Onno W Akkerman, Xavier Padanilam, Barbara Seaworth, Jan-Willem C Alffenaar

Pharmacy

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Research

1 Citation (Scopus)

Abstract

Anti-tuberculosis (TB) drugs can cause adverse drug reactions, particularly the older second-line drugs. Early intervention and adequate management of adverse drug reactions are important to prevent complications. Laboratory testing at baseline and during treatment, in addition to clinical monitoring, is protocolized to improve patient and treatment management. This chapter provides an overview of the most frequent and severe adverse effects caused by the first- and second-line drugs used for the treatment of tuberculosis. An approach on how to manage the adverse drugs effects is briefly described.

Original language	English
Title of host publication	Essential Tuberculosis
Editors	Giovanni Battista Migliori, Mario C. Raviglione
Place of Publication	Switzerland
Pages	121-130
Edition	1
DOIs	https://doi.org/10.1007/978-3-030-66703-0_13
Publication status	Published - 27 Jul 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/978-3-030-66703-0_13

https://hdl.handle.net/1959.11/73486

Handle.net

Persistent link

Cite this

@inbook{82988d0e6b3e4101bfc7fa0c3702ea19,

title = "Anti-Tuberculosis Drugs and Adverse Events",

abstract = "Anti-tuberculosis (TB) drugs can cause adverse drug reactions, particularly the older second-line drugs. Early intervention and adequate management of adverse drug reactions are important to prevent complications. Laboratory testing at baseline and during treatment, in addition to clinical monitoring, is protocolized to improve patient and treatment management. This chapter provides an overview of the most frequent and severe adverse effects caused by the first- and second-line drugs used for the treatment of tuberculosis. An approach on how to manage the adverse drugs effects is briefly described.",

author = "Kim, \{Hannah Yejin\} and Jin-Gun Cho and Akkerman, \{Onno W\} and Xavier Padanilam and Barbara Seaworth and Alffenaar, \{Jan-Willem C\}",

year = "2021",

month = jul,

day = "27",

doi = "10.1007/978-3-030-66703-0\_13",

language = "English",

isbn = "9783030667054",

pages = "121--130",

editor = "Migliori, \{Giovanni Battista\} and Raviglione, \{Mario C.\}",

booktitle = "Essential Tuberculosis",

edition = "1",

}

TY - CHAP

T1 - Anti-Tuberculosis Drugs and Adverse Events

AU - Kim, Hannah Yejin

AU - Cho, Jin-Gun

AU - Akkerman, Onno W

AU - Padanilam, Xavier

AU - Seaworth, Barbara

AU - Alffenaar, Jan-Willem C

PY - 2021/7/27

Y1 - 2021/7/27

N2 - Anti-tuberculosis (TB) drugs can cause adverse drug reactions, particularly the older second-line drugs. Early intervention and adequate management of adverse drug reactions are important to prevent complications. Laboratory testing at baseline and during treatment, in addition to clinical monitoring, is protocolized to improve patient and treatment management. This chapter provides an overview of the most frequent and severe adverse effects caused by the first- and second-line drugs used for the treatment of tuberculosis. An approach on how to manage the adverse drugs effects is briefly described.

AB - Anti-tuberculosis (TB) drugs can cause adverse drug reactions, particularly the older second-line drugs. Early intervention and adequate management of adverse drug reactions are important to prevent complications. Laboratory testing at baseline and during treatment, in addition to clinical monitoring, is protocolized to improve patient and treatment management. This chapter provides an overview of the most frequent and severe adverse effects caused by the first- and second-line drugs used for the treatment of tuberculosis. An approach on how to manage the adverse drugs effects is briefly described.

UR - https://doi.org/10.1007/978-3-030-66703-0

U2 - 10.1007/978-3-030-66703-0_13

DO - 10.1007/978-3-030-66703-0_13

M3 - Chapter

SN - 9783030667054

SN - 9783030667030

SP - 121

EP - 130

BT - Essential Tuberculosis

A2 - Migliori, Giovanni Battista

A2 - Raviglione, Mario C.

CY - Switzerland

ER -

Anti-Tuberculosis Drugs and Adverse Events

Abstract

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this